LYRA News and Press, Lyra Therapeutics Inc. From 09/13/21

WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passage...

Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-2...

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passage...

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages...

Lyra Therapeutics, Inc. (LYRA) Q2 2021 Earnings Conference Call August 09, 2021 04:30 PM ET Company Participants Stephanie Marks - Investor Relations, Argot Partners Maria Palasis - President & Chief Executive Officer Robert Kern - Chief Medical Officer Don Elsey - Chief Financial Officer...

- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 - - Licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets - - Positive topline results of LYR-210 PK study support 505(b)(2) NDA pathw...

Shares of Lyra Therapeutics Inc. (NASDAQ:LYRA) traded at a new 52-week low today of $6.36. So far today approximately 133,000 shares have been exchanged, as compared to an average 30-day volume of 129,000 shares. Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the ...

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and ...

Shares of Lyra Therapeutics Inc. (NASDAQ:LYRA) traded today at $6.80, breaking its 52-week low. This new low was reached on approximately average trading volume as 133,000 shares traded hands, while the average 30-day volume is approximately 129,000 shares. In the past 52 weeks, shares o...

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages...